Renaissance Capital logo

HengHong Technology Filed Terms, Nasdaq: HCPC

China-based distributor of traditional Chinese medicine products.

Industry: Industrials

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Industrials

Since our establishment, we have been focusing on the promotion and marketing of treatment and tonic traditional Chinese medicines. At present, treatment Chinese medicines are our major products, including mostly for cold and cough treatment, e.g. Ganmao Qingre Granules, Fenghan Ganmao Granules, Yinqiao Jiedu Granules, etc. Tonic medicines mainly include invigorating spleen granules for nourishing blood and tranquilizing nerves, pulse activating granules for nourishing yin and fluid, qi and blood nourishing, Shouwu Bushen tonic for tonifying kidney and essence, and Zhuangyao Jianshen pills for strengthening waist and kidney. In the future, we plan to increase our depth and strength in the promotion and marketing of tonic products, exploit the market potential of tonic products such as Zhuangyao Jianshen Pill, Suoxian Bushen Oral Liquid, Qizi Tianjing Oral Liquid, and build a series of medicinal liquor products, including Shouwu Bushen liquor, Morinda Officinal tonic liquor, Maoji Blood Tonic liquor, and Huichun tonic liquor. The main products that we sell are Chinese medicines for cold, flu and cough medicines, normally the demand is slightly higher during the flu season which is in winter and early spring.
more less
IPO Data
IPO File Date 03/27/2025
Offer Price
Price Range $6.00 - $7.00
Offer Shares (mm) 5.0
Deal Size ($mm) $33
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $6.00 - $7.00
Offer Shares (mm) 5.0
Deal Size ($mm) $33
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Kingswood Capital Markets
Company Data
Headquarters Chengmai County, China
Founded 2008
Employees at IPO 105

HengHong Technology (HCPC) Performance